– NORWAY, Oslo – Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, today announced the election of Dr. Marie Roskrow as the new Chairman of the Board of Directors, effective immediately.
“I’m very excited that Marie Roskrow is joining Lytix as the new Chairman of our board. Marie has a very strong and relevant background within immune-oncology and the finance sector, and I look forward to collaborating with her on further development and commercialization of our core technology and drug candidates,” said CEO, Øystein Rekdal.
About Dr. Marie Roskrow
Dr. Roskrow holds a medical degree and a Ph.D. in Immunology and currently serves as the Chairman of several international biotechnology companies.
In addition to high-level clinical and research positions, Dr. Roskrow has extensive experience as an investment banker, CEO, and Chairman in both private and listed companies, such as the GSF Research Institute (Munich), Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). She has also participated in dozens of public and private biotechnology and pharmaceutical merger and acquisition deals, company financings, and product in/out-licensing deals.
“I find Lytix Biopharma’s technology very unique and promising and look forward very much to using my expertise to help bring the company to commercial success,” said Dr. Marie Roskrow
For more information: https://www.lytixbiopharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.